Wells Fargo’s MoonLake Immunotherapeutics MLTX Stock Holding History

Wells Fargo’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$195K	Sell	10,000 -2,520	-20%	-$45.7K	﹤0.01%	5223
2026 Q1	$233K	Buy	12,520 +2,520	+25%	+$41.7K	﹤0.01%	4618
2025 Q4	$132K	Buy	10,000 +4,792	+92%	+$56.5K	﹤0.01%	5271
2025 Q3	$37.3K	Buy	5,208 +4,483	+618%	+$234K	﹤0.01%	5641
2025 Q2	$34.2K	Hold	725	–	–	﹤0.01%	5637
2025 Q1	$28.3K	Buy	725 +400	+123%	+$17.2K	﹤0.01%	5589
2024 Q4	$17.6K	Buy	325 +25	+8%	+$1.28K	﹤0.01%	5798
2024 Q3	$15.1K	Buy	300 +200	+200%	+$9.37K	﹤0.01%	5705
2024 Q2	$4.4K	Hold	100	–	–	﹤0.01%	5893
2024 Q1	$5.02K	Hold	100	–	–	﹤0.01%	5890
2023 Q4	$6.04K	Hold	100	–	–	﹤0.01%	5932
2023 Q3	$5.7K	Buy	+100	New	+$5.52K	﹤0.01%	5934

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Wells Fargo's MLTX Position: Q2 2026 in Review

Wells Fargo reduced its MoonLake Immunotherapeutics (MLTX) stake by 20% in Q2 2026, selling an estimated $45.7K and leaving 10,000 shares worth $195K. The position accounts for ﹤0.01% of the portfolio, ranked #5223.

Wells Fargo first reported a position in MLTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $233K in Q1 2026. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Wells Fargo held 10,000 shares of MoonLake Immunotherapeutics worth $195K as of Q2 2026.
Wells Fargo sold 2,520 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $45.7K.
MoonLake Immunotherapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5223 holding.
Wells Fargo first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 12 quarters since.
Wells Fargo's MoonLake Immunotherapeutics position peaked at $233K in Q1 2026.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.